Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aclaris Therapeutics, Inc.ACRS · Entity 5041 | Director | June 04, 2026 | June 08, 2026 |
| Bausch Health Companies Inc.BHC · Entity 4363 | President, Ortho-Dermatologics | December 04, 2020 | December 08, 2020 |
| Clearside Biomedical, Inc.CLSD · Entity 82875 | Director | June 20, 2024 | June 21, 2024 |
| PhaseBio Pharmaceuticals IncPHAS · Entity 113305 | Director | May 19, 2023 | May 19, 2023 |
| STRATA Skin Sciences, Inc.SSKN · Entity 72980 | Director | July 05, 2023 | July 07, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aclaris Therapeutics, Inc.
Report date June 04, 2026 · Filed June 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 45,105 |
Reported balance
After 2026-06-05 transaction · row 1
1 source rowRow 1 · 2026-06-05 · Exercise / conversion · Acquired 11,580 · Balance 45,105 F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.71 · Expires 2036-06-03 | Direct | 42,350 |
Reported balance
After 2026-06-04 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-04 · Grant · Acquired 42,350 · Balance 42,350 F2: The shares subject to this stock option will vest in twelve equal monthly installments commencing on July 4, 2026, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2025 Equity Incentive Plan, or the Plan) through each such vesting date. F3: This grant was made pursuant to the issuer's tenth amended and restated non-employee director compensation policy. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 10,987 |
Reported balance
After 2026-06-04 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-04 · Grant · Acquired 10,987 · Balance 10,987 F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F4: The shares underlying these restricted stock units will vest in one installment on June 4, 2027, subject to the Reporting Person's Continuous Service (as defined in the Plan) as of such date. F3: This grant was made pursuant to the issuer's tenth amended and restated non-employee director compensation policy. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-06-05 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-06-05 · Exercise / conversion · Disposed 11,580 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F5: The shares underlying these restricted stock units vested on June 5, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
F2: The shares subject to this stock option will vest in twelve equal monthly installments commencing on July 4, 2026, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2025 Equity Incentive Plan, or the Plan) through each such vesting date.
F3: This grant was made pursuant to the issuer's tenth amended and restated non-employee director compensation policy.
F4: The shares underlying these restricted stock units will vest in one installment on June 4, 2027, subject to the Reporting Person's Continuous Service (as defined in the Plan) as of such date.
F5: The shares underlying these restricted stock units vested on June 5, 2026.
Bausch Health Companies Inc.
Report date December 04, 2020 · Filed December 08, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Shares, No Par ValueSEC Table I · non-derivative | Direct | 235,035 |
Ending reported balance
After 2020-12-04 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2020-12-04 · Exercise / conversion · Acquired 114,055 · Balance 349,090 Row 2 · 2020-12-04 · Sale · Disposed 114,055 · Balance 235,035 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.80 to $19.82 per share. The Reporting Person will provide to the Commission, the Issuer and any stockholder of the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range provided in this footnote. |
| Non-qualified Stock Options (right To Purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $14.38 · Expires 2027-03-01 | Direct | 0 |
Reported balance
After 2020-12-04 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-12-04 · Exercise / conversion · Disposed 114,055 · Balance 0 F2: The options vest in equal installments on each of the first three anniversaries of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.80 to $19.82 per share. The Reporting Person will provide to the Commission, the Issuer and any stockholder of the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range provided in this footnote.
F2: The options vest in equal installments on each of the first three anniversaries of the date of grant.
Clearside Biomedical, Inc.
Report date June 20, 2024 · Filed June 21, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.15 · Expires 2034-06-19 | Direct | 45,000 |
Reported balance
After 2024-06-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-06-20 · Grant · Acquired 45,000 · Balance 45,000 F1: The shares underlying this option vest in full on the earlier of the Issuer's next annual meeting of stockholders or June 20, 2025, subject to the Reporting Person's continuous service as of such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option vest in full on the earlier of the Issuer's next annual meeting of stockholders or June 20, 2025, subject to the Reporting Person's continuous service as of such vesting date.
PhaseBio Pharmaceuticals Inc
Report date May 19, 2023 · Filed May 19, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,538 |
Reported balance
After 2023-05-19 transaction · row 1
1 source rowRow 1 · 2023-05-19 · Exercise / conversion · Acquired 2,538 · Balance 2,538 F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of PhaseBio Pharmaceuticals, Inc. common stock. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-05-19 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-05-19 · Exercise / conversion · Disposed 2,538 · Balance 0 F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of PhaseBio Pharmaceuticals, Inc. common stock. F2: The RSUs vested and were delivered to the Reporting Person on the one-year anniversary of the grant date, subject to the Reporting Person's continuous service through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of PhaseBio Pharmaceuticals, Inc. common stock.
F2: The RSUs vested and were delivered to the Reporting Person on the one-year anniversary of the grant date, subject to the Reporting Person's continuous service through such date.
STRATA Skin Sciences, Inc.
Report date July 05, 2023 · Filed July 07, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| SSKN Common StockSEC Table I · non-derivative | Direct | 109,724 |
Reported balance
After 2023-07-05 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-07-05 · Grant · Acquired 36,408 · Balance 109,724 F1: Represents Restricted Stock Units issued to the recipient in lieu of a portion of the recipient's Board Compensation on July 5, 2023, utilizing the closing price on July 3, 2023. The Restricted Stock will vest at 100%, in equal quarterly installments, over a 12 month period. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents Restricted Stock Units issued to the recipient in lieu of a portion of the recipient's Board Compensation on July 5, 2023, utilizing the closing price on July 3, 2023. The Restricted Stock will vest at 100%, in equal quarterly installments, over a 12 month period.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 05, 2026 Filed Jun 8, 2026 20:15 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted Stock Units · Derivative | 11,580 | $0.00 | $0.00 |
DisclosureSEC source: 0001674278-26-000002 · form4-06082026_040603.xml · derivative · entry 4 Humphries William D. · CIK 0001674278 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,580 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F5 · derivative.exercise_date: The shares underlying these restricted stock units vested on June 5, 2026. F5 · derivative.expiration_date: The shares underlying these restricted stock units vested on June 5, 2026. Read SEC document |
| June 05, 2026 Filed Jun 8, 2026 20:15 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 11,580 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001674278-26-000002 · form4-06082026_040603.xml · nonDerivative · entry 1 Humphries William D. · CIK 0001674278 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,105 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document |
| June 04, 2026 Filed Jun 8, 2026 20:15 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | GrantRestricted Stock Units · Derivative | 10,987 | $0.00 | $0.00 |
DisclosureSEC source: 0001674278-26-000002 · form4-06082026_040603.xml · derivative · entry 3 Humphries William D. · CIK 0001674278 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,987 Underlying: Common Stock · 10,987 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F4 · derivative.exercise_date: The shares underlying these restricted stock units will vest in one installment on June 4, 2027, subject to the Reporting Person's Continuous Service (as defined in the Plan) as of such date. F4 · derivative.expiration_date: The shares underlying these restricted stock units will vest in one installment on June 4, 2027, subject to the Reporting Person's Continuous Service (as defined in the Plan) as of such date. F3 · balance_after: This grant was made pursuant to the issuer's tenth amended and restated non-employee director compensation policy. Read SEC document |
| June 04, 2026 Filed Jun 8, 2026 20:15 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | GrantStock Option (Right to Buy) · Derivative | 42,350 | $0.00 Strike: $4.71 | $0.00 |
DisclosureSEC source: 0001674278-26-000002 · form4-06082026_040603.xml · derivative · entry 2 Humphries William D. · CIK 0001674278 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,350 Underlying: Common Stock · 42,350 shares Expires 2036-06-03 F2 · derivative.exercise_date: The shares subject to this stock option will vest in twelve equal monthly installments commencing on July 4, 2026, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2025 Equity Incentive Plan, or the Plan) through each such vesting date. F3 · balance_after: This grant was made pursuant to the issuer's tenth amended and restated non-employee director compensation policy. Read SEC document |
| June 06, 2025 Filed Jun 9, 2025 20:20 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted Stock Units · Derivative | 4,793 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-016249 · form4-06092025_040606.xml · derivative · entry 4 Humphries William D. · CIK 0001674278 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,793 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F5 · derivative.exercise_date: The shares underlying these restricted stock units vested on June 6, 2025. F5 · derivative.expiration_date: The shares underlying these restricted stock units vested on June 6, 2025. Read SEC document |
| June 06, 2025 Filed Jun 9, 2025 20:20 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 4,793 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-016249 · form4-06092025_040606.xml · nonDerivative · entry 1 Humphries William D. · CIK 0001674278 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,525 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document |
| June 05, 2025 Filed Jun 9, 2025 20:20 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | GrantRestricted Stock Units · Derivative | 11,580 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-016249 · form4-06092025_040606.xml · derivative · entry 3 Humphries William D. · CIK 0001674278 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,580 Underlying: Common Stock · 11,580 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F4 · derivative.exercise_date: The shares underlying these restricted stock units will vest in one installment on June 5, 2026, subject to the Reporting Person's Continuous Service (as defined in the Plan) as of such date. F4 · derivative.expiration_date: The shares underlying these restricted stock units will vest in one installment on June 5, 2026, subject to the Reporting Person's Continuous Service (as defined in the Plan) as of such date. F3 · balance_after: This grant was made pursuant to the issuer's tenth amended and restated non-employee director compensation policy. Read SEC document |
| June 05, 2025 Filed Jun 9, 2025 20:20 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | GrantStock Option (Right to Buy) · Derivative | 42,350 | $0.00 Strike: $1.56 | $0.00 |
DisclosureSEC source: 0001415889-25-016249 · form4-06092025_040606.xml · derivative · entry 2 Humphries William D. · CIK 0001674278 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,350 Underlying: Common Stock · 42,350 shares Expires 2035-06-04 F2 · derivative.exercise_date: The shares subject to this stock option will vest in twelve equal monthly installments commencing on July 5, 2025, subject to the Reporting Person's Continuous Service (as defined in the Plan) through each such vesting date. F3 · balance_after: This grant was made pursuant to the issuer's tenth amended and restated non-employee director compensation policy. Read SEC document |
| June 20, 2024 Filed Jun 21, 2024 20:15 UTC | Clearside Biomedical, Inc. CLSD · Entity 82875 | GrantStock Option (right to buy) · Derivative | 45,000 | $0.00 Strike: $1.15 | $0.00 |
DisclosureSEC source: 0001415889-24-017822 · form4-06212024_040609.xml · derivative · entry 1 Humphries William D. · CIK 0001674278 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2034-06-19 F1 · derivative.exercise_date: The shares underlying this option vest in full on the earlier of the Issuer's next annual meeting of stockholders or June 20, 2025, subject to the Reporting Person's continuous service as of such vesting date. Read SEC document |
| June 06, 2024 Filed Jun 10, 2024 20:15 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | GrantRestricted Stock Units · Derivative | 4,793 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-016197 · form4-06102024_040613.xml · derivative · entry 2 Humphries William D. · CIK 0001674278 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,793 Underlying: Common Stock · 4,793 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F4 · derivative.exercise_date: The shares underlying these restricted stock units will vest on June 6, 2025, subject to the Reporting Person's continuous service through such date. F4 · derivative.expiration_date: The shares underlying these restricted stock units will vest on June 6, 2025, subject to the Reporting Person's continuous service through such date. F2 · balance_after: This grant was made pursuant to the issuer's ninth amended and restated non-employee director compensation policy. Read SEC document |
| June 06, 2024 Filed Jun 10, 2024 20:15 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | GrantStock Option (Right to Buy) · Derivative | 15,750 | $0.00 Strike: $1.03 | $0.00 |
DisclosureSEC source: 0001415889-24-016197 · form4-06102024_040613.xml · derivative · entry 1 Humphries William D. · CIK 0001674278 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,750 Underlying: Common Stock · 15,750 shares Expires 2034-06-05 F1 · derivative.exercise_date: The shares subject to this option will vest in twelve equal monthly installments commencing July 6, 2024, subject to Reporting Person's continuous service through each such date. F2 · balance_after: This grant was made pursuant to the issuer's ninth amended and restated non-employee director compensation policy. Read SEC document |
| June 01, 2024 Filed Jun 4, 2024 20:30 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted Stock Units · Derivative | 4,660 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-015364 · form4-06042024_040610.xml · derivative · entry 2 Humphries William D. · CIK 0001674278 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,660 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F2 · derivative.exercise_date: The shares underlying these restricted stock units vested on June 1, 2024. F2 · derivative.expiration_date: The shares underlying these restricted stock units vested on June 1, 2024. Read SEC document |
| June 01, 2024 Filed Jun 4, 2024 20:30 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 4,660 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-015364 · form4-06042024_040610.xml · nonDerivative · entry 1 Humphries William D. · CIK 0001674278 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,732 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document |
| September 22, 2023 Filed Sep 22, 2023 20:35 UTC | Clearside Biomedical, Inc. CLSD · Entity 82875 | Exercise / conversionStock Option (right to buy) · Derivative | 22,727 | $0.00 Strike: $0.40 | $0.00 |
DisclosureSEC source: 0001209191-23-050381 · doc4.xml · derivative · entry 2 Humphries William D. · CIK 0001674278 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 22,727 shares Expires 2023-10-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Fully vested and exercisable. Read SEC document |
| September 22, 2023 Filed Sep 22, 2023 20:35 UTC | Clearside Biomedical, Inc. CLSD · Entity 82875 | Exercise / conversionCommon Stock | 22,727 | $0.40 | $9,090.80 |
DisclosureSEC source: 0001209191-23-050381 · doc4.xml · nonDerivative · entry 1 Humphries William D. · CIK 0001674278 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,040 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 05, 2023 Filed Jul 7, 2023 16:06 UTC | STRATA Skin Sciences, Inc. SSKN · Entity 72980 | GrantSSKN Common Stock | 36,408 | $1.03 | $37,500.24 |
DisclosureSEC source: 0001051514-23-000029 · form4.xml · nonDerivative · entry 1 Humphries William D. · CIK 0001674278 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 109,724 F1 · security: Represents Restricted Stock Units issued to the recipient in lieu of a portion of the recipient's Board Compensation on July 5, 2023, utilizing the closing price on July 3, 2023. The Restricted Stock will vest at 100%, in equal quarterly installments, over a 12 month period. Read SEC document |
| June 22, 2023 Filed Jun 23, 2023 20:38 UTC | Clearside Biomedical, Inc. CLSD · Entity 82875 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $1.31 | $0.00 |
DisclosureSEC source: 0001209191-23-039421 · doc4.xml · derivative · entry 1 Humphries William D. · CIK 0001674278 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2033-06-21 F1 · derivative.exercise_date: The shares underlying this option vest in full on the earlier of the Issuer's next annual meeting of stockholders or June 22, 2024, subject to the Reporting Person's continuous service as of such vesting date. Read SEC document |
| June 02, 2023 Filed Jun 5, 2023 21:12 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted Stock Units · Derivative | 4,507 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-034477 · doc4.xml · derivative · entry 4 Humphries William D. · CIK 0001674278 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,507 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F5 · derivative.exercise_date: The shares underlying these restricted stock units vested on June 2, 2023. F5 · derivative.expiration_date: The shares underlying these restricted stock units vested on June 2, 2023. Read SEC document |
| June 02, 2023 Filed Jun 5, 2023 21:12 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 4,507 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-034477 · doc4.xml · nonDerivative · entry 1 Humphries William D. · CIK 0001674278 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,072 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document |
| June 01, 2023 Filed Jun 5, 2023 21:12 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | GrantRestricted Stock Units · Derivative | 4,660 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-034477 · doc4.xml · derivative · entry 3 Humphries William D. · CIK 0001674278 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,660 Underlying: Common Stock · 4,660 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F2 · derivative.exercise_date: This grant was made pursuant to the issuer's ninth amended and restated non-employee director compensation policy. F4 · derivative.exercise_date: The shares underlying these restricted stock units will vest on June 1, 2024, subject to the Reporting Person's continuous service through such date. F4 · derivative.expiration_date: The shares underlying these restricted stock units will vest on June 1, 2024, subject to the Reporting Person's continuous service through such date. Read SEC document |
| June 01, 2023 Filed Jun 5, 2023 21:12 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | GrantStock Option (Right to Buy) · Derivative | 15,750 | $0.00 Strike: $8.70 | $0.00 |
DisclosureSEC source: 0001209191-23-034477 · doc4.xml · derivative · entry 2 Humphries William D. · CIK 0001674278 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,750 Underlying: Common Stock · 15,750 shares Expires 2033-05-31 F2 · derivative.exercise_date: This grant was made pursuant to the issuer's ninth amended and restated non-employee director compensation policy. F3 · derivative.exercise_date: The shares subject to this option will vest in twelve equal monthly installments commencing July 1, 2023, subject to Reporting Person's continuous service through each such date. Read SEC document |
| May 19, 2023 Filed May 19, 2023 16:18 UTC | PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 | Exercise / conversionRestricted Stock Units · Derivative | 2,538 | $0.00 | $0.00 |
DisclosureSEC source: 0001169245-23-000031 · wf-form4_168452745624931.xml · derivative · entry 2 Humphries William D. · CIK 0001674278 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,538 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of PhaseBio Pharmaceuticals, Inc. common stock. F2 · derivative.exercise_date: The RSUs vested and were delivered to the Reporting Person on the one-year anniversary of the grant date, subject to the Reporting Person's continuous service through such date. F2 · derivative.expiration_date: The RSUs vested and were delivered to the Reporting Person on the one-year anniversary of the grant date, subject to the Reporting Person's continuous service through such date. Read SEC document |
| May 19, 2023 Filed May 19, 2023 16:18 UTC | PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 | Exercise / conversionCommon Stock | 2,538 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001169245-23-000031 · wf-form4_168452745624931.xml · nonDerivative · entry 1 Humphries William D. · CIK 0001674278 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,538 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of PhaseBio Pharmaceuticals, Inc. common stock. Read SEC document |
| June 22, 2022 Filed Jun 24, 2022 20:22 UTC | Clearside Biomedical, Inc. CLSD · Entity 82875 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $1.62 | $0.00 |
DisclosureSEC source: 0001209191-22-039222 · doc4.xml · derivative · entry 1 Humphries William D. · CIK 0001674278 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2032-06-21 F1 · derivative.exercise_date: The shares underlying this option vest in full on the earlier of the Issuer's next annual meeting of stockholders or June 22, 2023. Read SEC document |
| June 03, 2022 Filed Jun 6, 2022 21:18 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted Stock Units · Derivative | 3,356 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-034585 · doc4.xml · derivative · entry 4 Humphries William D. · CIK 0001674278 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,356 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F5 · derivative.exercise_date: The shares underlying these restricted stock units vested on June 3, 2022. F5 · derivative.expiration_date: The shares underlying these restricted stock units vested on June 3, 2022. Read SEC document |
| June 03, 2022 Filed Jun 6, 2022 21:18 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 3,356 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-034585 · doc4.xml · nonDerivative · entry 1 Humphries William D. · CIK 0001674278 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,565 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document |
| June 02, 2022 Filed Jun 6, 2022 21:18 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | GrantRestricted Stock Units · Derivative | 4,507 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-034585 · doc4.xml · derivative · entry 3 Humphries William D. · CIK 0001674278 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,507 Underlying: Common Stock · 4,507 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F2 · derivative.exercise_date: This grant was made pursuant to the issuer's seventh amended and restated non-employee director compensation policy. F4 · derivative.exercise_date: The shares underlying these restricted stock units will vest on June 2, 2023, subject to the Reporting Person's continuous service through such date. F4 · derivative.expiration_date: The shares underlying these restricted stock units will vest on June 2, 2023, subject to the Reporting Person's continuous service through such date. Read SEC document |
| June 02, 2022 Filed Jun 6, 2022 21:18 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | GrantStock Option (Right to Buy) · Derivative | 15,750 | $0.00 Strike: $14.48 | $0.00 |
DisclosureSEC source: 0001209191-22-034585 · doc4.xml · derivative · entry 2 Humphries William D. · CIK 0001674278 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,750 Underlying: Common Stock · 15,750 shares Expires 2032-06-01 F2 · derivative.exercise_date: This grant was made pursuant to the issuer's seventh amended and restated non-employee director compensation policy. F3 · derivative.exercise_date: The shares subject to this option will vest in twelve equal monthly installments commencing July 2, 2022, subject to Reporting Person's continuous service through each such date. Read SEC document |
| May 19, 2022 Filed May 20, 2022 16:46 UTC | PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 | GrantRestricted Stock Units · Derivative | 3,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001169245-22-000066 · wf-form4_165307957678194.xml · derivative · entry 2 Humphries William D. · CIK 0001674278 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,750 Underlying: Common Stock · 3,750 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of PhaseBio Pharmaceuticals, Inc. common stock. F3 · derivative.exercise_date: The RSUs shall vest and be delivered to the Reporting Person on the earlier of the one-year anniversary of the grant date or the 2023 annual stockholder meeting, subject to the Reporting Person's continuous service through such date. F3 · derivative.expiration_date: The RSUs shall vest and be delivered to the Reporting Person on the earlier of the one-year anniversary of the grant date or the 2023 annual stockholder meeting, subject to the Reporting Person's continuous service through such date. Read SEC document |
| May 19, 2022 Filed May 20, 2022 16:46 UTC | PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 | GrantNon-employee Director Stock Option (right to buy) · Derivative | 17,500 | $0.00 Strike: $0.84 | $0.00 |
DisclosureSEC source: 0001169245-22-000066 · wf-form4_165307957678194.xml · derivative · entry 1 Humphries William D. · CIK 0001674278 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 17,500 shares Expires 2032-05-18 F1 · derivative.exercise_date: The shares subject to the option shall vest on the earlier of the one-year anniversary of the grant date or the 2023 annual stockholder meeting, subject to the Reporting Person's continuous service through such date. Read SEC document |
| May 19, 2022 Filed Jun 10, 2022 16:20 UTC Amendment | PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 | GrantRestricted Stock Units · Derivative | 2,538 | $0.00 | $0.00 |
DisclosureSEC source: 0001169245-22-000081 · wf-form4a_165489241494222.xml · derivative · entry 2 Humphries William D. · CIK 0001674278 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,538 Underlying: Common Stock · 2,538 shares Expires not disclosed F3 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of PhaseBio Pharmaceuticals, Inc. common stock. F1 · shares: This amendment is being filed to correct an error in the total Stock Options and RSUs acquired by the Reporting Person. All other information set forth in the May 20, 2022 Form 4 remains correct. F4 · derivative.exercise_date: The RSUs shall vest and be delivered to the Reporting Person on the earlier of the one-year anniversary of the grant date or the 2023 annual stockholder meeting, subject to the Reporting Person's continuous service through such date. F4 · derivative.expiration_date: The RSUs shall vest and be delivered to the Reporting Person on the earlier of the one-year anniversary of the grant date or the 2023 annual stockholder meeting, subject to the Reporting Person's continuous service through such date. Read SEC document |
| May 19, 2022 Filed Jun 10, 2022 16:20 UTC Amendment | PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 | GrantNon-employee Director Stock Option (right to buy) · Derivative | 11,842 | $0.00 Strike: $0.84 | $0.00 |
DisclosureSEC source: 0001169245-22-000081 · wf-form4a_165489241494222.xml · derivative · entry 1 Humphries William D. · CIK 0001674278 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,842 Underlying: Common Stock · 11,842 shares Expires 2032-05-18 F1 · shares: This amendment is being filed to correct an error in the total Stock Options and RSUs acquired by the Reporting Person. All other information set forth in the May 20, 2022 Form 4 remains correct. F2 · derivative.exercise_date: The shares subject to the option shall vest on the earlier of the one-year anniversary of the grant date or the 2023 annual stockholder meeting, subject to the Reporting Person's continuous service through such date. Read SEC document |
| March 25, 2022 Filed Mar 28, 2022 17:03 UTC | STRATA Skin Sciences, Inc. SSKN · Entity 72980 | PurchaseSSKN Common Stock | 16,950 | $1.73 | $29,384.52 |
DisclosureSEC source: 0001051514-22-000035 · form4.xml · nonDerivative · entry 1 Humphries William D. · CIK 0001674278 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 484,440 Read SEC document |
| March 24, 2022 Filed Mar 24, 2022 20:32 UTC | STRATA Skin Sciences, Inc. SSKN · Entity 72980 | PurchaseSSKN Common Stock | 14,783 | $1.58 | $23,386.71 |
DisclosureSEC source: 0001051514-22-000033 · form4.xml · nonDerivative · entry 1 Humphries William D. · CIK 0001674278 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 467,490 Read SEC document |
| January 10, 2022 Filed Jan 11, 2022 21:45 UTC | Clearside Biomedical, Inc. CLSD · Entity 82875 | Exercise / conversionStock Option (right to buy) · Derivative | 22,727 | $0.00 Strike: $0.15 | $0.00 |
DisclosureSEC source: 0001209191-22-002893 · doc4.xml · derivative · entry 2 Humphries William D. · CIK 0001674278 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 22,727 shares Expires 2022-01-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Fully vested and exercisable. Read SEC document |
| January 10, 2022 Filed Jan 11, 2022 21:45 UTC | Clearside Biomedical, Inc. CLSD · Entity 82875 | Exercise / conversionCommon Stock | 22,727 | $0.15 | $3,409.05 |
DisclosureSEC source: 0001209191-22-002893 · doc4.xml · nonDerivative · entry 1 Humphries William D. · CIK 0001674278 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,313 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 14, 2021 Filed Sep 15, 2021 08:15 UTC | PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 | GrantNon-employee Director Stock Option (right to buy) · Derivative | 28,000 | $0.00 Strike: $2.80 | $0.00 |
DisclosureSEC source: 0001169245-21-000097 · wf-form4_163170811314129.xml · derivative · entry 1 Humphries William D. · CIK 0001674278 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,000 Underlying: Common Stock · 28,000 shares Expires 2031-09-14 F1 · derivative.exercise_date: The shares subject to the option shall vest in equal monthly installments over 36 months from September 14, 2021, subject to the reporting person's continued service through each such date. Read SEC document |
| August 20, 2021 Filed Aug 23, 2021 16:44 UTC | STRATA Skin Sciences, Inc. SSKN · Entity 72980 | GrantNon-Qualified Stock Option Agreement for SSKN Common Stock · Derivative | 411,124 | $0.00 Strike: $1.42 | $0.00 |
DisclosureSEC source: 0001051514-21-000057 · form4.xml · derivative · entry 1 Humphries William D. · CIK 0001674278 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 452,707 Underlying: Common Stock · 411,124 shares Expires 2031-08-20 F1 · shares: Options vest, commensing on the first anniversary, in equal annual installments, over a 4 year period. Read SEC document |
| July 20, 2021 Filed Jul 21, 2021 17:28 UTC | STRATA Skin Sciences, Inc. SSKN · Entity 72980 | GrantSSKN Common Stock | 21,583 | $0.00 | $0.00 |
DisclosureSEC source: 0001051514-21-000034 · form4.xml · nonDerivative · entry 2 Humphries William D. · CIK 0001674278 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,583 F2 · security: Represents Restricted Stock Units issued to the recipient, in lieu of a portion of the recipient's Board Compensation, on July 20, 2021. The Restricted Stock Units generally vest at 100% on the first anniversary of the date of grant. RSUs have a minimum one year vesting unless as permitted under Section 7.3(c). Read SEC document |
| July 20, 2021 Filed Jul 21, 2021 17:28 UTC | STRATA Skin Sciences, Inc. SSKN · Entity 72980 | GrantSSKN Common Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001051514-21-000034 · form4.xml · nonDerivative · entry 1 Humphries William D. · CIK 0001674278 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 F1 · security: Represents Restricted Stock Units issued to the recipient, per the Director Compensation Program relating to recipient becoming a board member. The Restricted Stock Units generally vest 100% on the first anniversary date. RSUs have a minimum one year vesting unless as permitted under Section 7.3(c). Read SEC document |
| June 10, 2021 Filed Jun 11, 2021 21:35 UTC | Clearside Biomedical, Inc. CLSD · Entity 82875 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $3.11 | $0.00 |
DisclosureSEC source: 0001209191-21-039953 · doc4.xml · derivative · entry 1 Humphries William D. · CIK 0001674278 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2031-06-09 F1 · derivative.exercise_date: The shares underlying this option vest in full on the earlier of the Issuer's next annual meeting of stockholders or June 10, 2022. Read SEC document |
| June 03, 2021 Filed Jun 4, 2021 23:57 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | GrantRestricted Stock Units · Derivative | 3,356 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-038446 · doc4.xml · derivative · entry 2 Humphries William D. · CIK 0001674278 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,356 Underlying: Common Stock · 3,356 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F1 · derivative.exercise_date: This grant was made pursuant to the issuer's fifth amended and restated non-employee director compensation policy. F4 · derivative.exercise_date: The shares underlying these restricted stock units will vest on June 3, 2022, subject to the Reporting Person's continuous service through such date. F4 · derivative.expiration_date: The shares underlying these restricted stock units will vest on June 3, 2022, subject to the Reporting Person's continuous service through such date. Read SEC document |
| June 03, 2021 Filed Jun 4, 2021 23:57 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | GrantStock Option (Right to Buy) · Derivative | 12,250 | $0.00 Strike: $21.90 | $0.00 |
DisclosureSEC source: 0001209191-21-038446 · doc4.xml · derivative · entry 1 Humphries William D. · CIK 0001674278 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,250 Underlying: Common Stock · 12,250 shares Expires 2031-06-02 F1 · derivative.exercise_date: This grant was made pursuant to the issuer's fifth amended and restated non-employee director compensation policy. F2 · derivative.exercise_date: The shares subject this option will vest in twelve equal monthly installments commencing July 3, 2021, subject to Reporting Person's continuous service through each such date. Read SEC document |
| December 04, 2020 Filed Dec 8, 2020 21:23 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | Exercise / conversionNon-qualified Stock Options (right To Purchase) · Derivative | 114,055 | $0.00 Strike: $14.38 | $0.00 |
DisclosureSEC source: 0001127602-20-030840 · form4.xml · derivative · entry 3 Humphries William D. · CIK 0001674278 · President, Ortho-Dermatologics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares, No Par Value · 114,055 shares Expires 2027-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The options vest in equal installments on each of the first three anniversaries of the date of grant. Read SEC document |
| December 04, 2020 Filed Dec 8, 2020 21:23 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | SaleCommon Shares, No Par Value | 114,055 | $19.87 | $2,266,398.31 |
DisclosureSEC source: 0001127602-20-030840 · form4.xml · nonDerivative · entry 2 Humphries William D. · CIK 0001674278 · President, Ortho-Dermatologics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 235,035 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.80 to $19.82 per share. The Reporting Person will provide to the Commission, the Issuer and any stockholder of the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range provided in this footnote. Read SEC document |
| December 04, 2020 Filed Dec 8, 2020 21:23 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | Exercise / conversionCommon Shares, No Par Value | 114,055 | $14.38 | $1,640,110.90 |
DisclosureSEC source: 0001127602-20-030840 · form4.xml · nonDerivative · entry 1 Humphries William D. · CIK 0001674278 · President, Ortho-Dermatologics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 349,090 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 27, 2020 Filed Nov 30, 2020 21:50 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | Exercise / conversionNon-qualified Stock Options (right To Purchase) · Derivative | 13,663 | $0.00 Strike: $14.38 | $0.00 |
DisclosureSEC source: 0001127602-20-030120 · form4.xml · derivative · entry 9 Humphries William D. · CIK 0001674278 · President, Ortho-Dermatologics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,055 Underlying: Common Shares, No Par Value · 13,663 shares Expires 2027-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The options vest in equal installments on each of the first three anniversaries of the date of grant. Read SEC document |
| November 27, 2020 Filed Nov 30, 2020 21:50 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | SaleCommon Shares, No Par Value | 13,663 | $19.63 | $268,207.42 |
DisclosureSEC source: 0001127602-20-030120 · form4.xml · nonDerivative · entry 6 Humphries William D. · CIK 0001674278 · President, Ortho-Dermatologics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 235,035 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.63 to $19.635 per share. The Reporting Person will provide to the Commission, the Issuer and any stockholder of the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range provided in this footnote. Read SEC document |
| November 27, 2020 Filed Nov 30, 2020 21:50 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | Exercise / conversionCommon Shares, No Par Value | 13,663 | $14.38 | $196,473.94 |
DisclosureSEC source: 0001127602-20-030120 · form4.xml · nonDerivative · entry 5 Humphries William D. · CIK 0001674278 · President, Ortho-Dermatologics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 248,698 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 24, 2020 Filed Nov 30, 2020 21:50 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | Exercise / conversionNon-qualified Stock Options (right To Purchase) · Derivative | 21,658 | $0.00 Strike: $14.38 | $0.00 |
DisclosureSEC source: 0001127602-20-030120 · form4.xml · derivative · entry 8 Humphries William D. · CIK 0001674278 · President, Ortho-Dermatologics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,718 Underlying: Common Shares, No Par Value · 21,658 shares Expires 2027-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The options vest in equal installments on each of the first three anniversaries of the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.